Showing results (501-510 of 700) with videos related to

Sort By:
Pageof 70
Journal of Hypertension|December 30, 2022
Effect of finerenone on ambulatory blood pressure in chronic kidney disease in type 2 diabetesRajiv Agarwal, Luis M Ruilope, Gema Ruiz-Hurtado, et al.
Frontiers in Clinical Diabetes and Healthcare|March 30, 2023
Liraglutide Lowers Palmitoleate Levels in Type 2 Diabetes. A Post Hoc Analysis of the LIRAFLAME Randomized Placebo-Controlled TrialAsger Wretlind, Emilie Hein Zobel, Andressa de Zawadzki, et al.
Kidney International|July 16, 2017
Challenges in conducting clinical trials in nephrology: conclusions from a Kidney Disease-Improving Global Outcomes (KDIGO) Controversies ConferenceColin Baigent, William G Herrington, Josef Coresh, et al.
Diabetes, Obesity & Metabolism|October 10, 2023
Efficacy of finerenone in patients with type 2 diabetes, chronic kidney disease and altered markers of liver steatosis and fibrosis: A FIDELITY subgroup analysisNikolaos Perakakis, Stefan R Bornstein, Andreas L Birkenfeld, et al.
Advances in Therapy|March 24, 2026
Evidence-Based Positioning of Sodium-Glucose Co-transporter 2 Inhibitors and Glucagon-Like Peptide 1 Receptor Agonists in the Management of Chronic Kidney Disease with Type 2 Diabetes and Overweight or Obesity: A Systematic Literature ReviewYehuda Handelsman, Alice Y Y Cheng, Gian Paolo Fadini, et al.
European Heart Journal|April 22, 2025
Incident hyperkalaemia risk model in chronic kidney disease and diabetes: the FIDELITY programmeJoão Pedro Ferreira, Stefan D Anker, Biff F Palmer, et al.
BMJ Open Diabetes Research & Care|December 3, 2014
Retinopathy and clinical outcomes in patients with type 2 diabetes mellitus, chronic kidney disease, and anemiaNatalie A Bello, Marc A Pfeffer, Hicham Skali, et al.
Annals of Internal Medicine|December 4, 2023
Impact of Finerenone-Induced Albuminuria Reduction on Chronic Kidney Disease Outcomes in Type 2 Diabetes : A Mediation AnalysisRajiv Agarwal, Wanzhu Tu, Alfredo E Farjat, et al.
JAMA Cardiology|June 14, 2023
Modifiability of Composite Cardiovascular Risk Associated With Chronic Kidney Disease in Type 2 Diabetes With FinerenoneRajiv Agarwal, Bertram Pitt, Peter Rossing, et al.
Annals of Internal Medicine|December 5, 2022
Effects of Dapagliflozin on Hospitalizations in Patients With Chronic Kidney Disease : A Post Hoc Analysis of DAPA-CKDMeir Schechter, Niels Jongs, Glenn M Chertow, et al.
Pageof 70